Pharmacotherapy for the obese patient.

Lori M Dickerson, Peter J Carek

Journal: Primary care 2009;36(2):407-15

PMID: 19501251

Full Text on Elsevier Science View on PubMed

Abstract

The long-term safety of many antiobesity pharmacologic regimens has not been adequately evaluated. If recommended and prescribed, pharmacologic agents should be an adjunct to a structured diet and exercise regimen. Unfortunately, weight gain after discontinuation of antiobesity agents is common. In addition, the effect of weight loss obtained through the use of pharmacotherapeutic agents on overall morbidity and mortality has not been established.

Address: Department of Family Medicine, Medical University of South Carolina, 9228 Medical Plaza Drive, Charleston, SC 29406, USA. [email protected]

DOI: 10.1016/j.pop.2009.01.004

Link outs

Free resources

Medical:

https://medlineplus.gov/obesity.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Adrenergic Agents, Anti-Obesity Agents, Appetite Depressants, Body Mass Index, Humans, Obesity, Serotonin Agents